Is SUPN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Supernus Pharmaceuticals (SUPN) rests on Qelbree as the volume anchor in ADHD: Qelbree is the largest single product at ~$89 million in quarterly net sales and grew ~15% year over year. The bear case rests on the legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue. Analysts covering it publish targets from $55.00 to $67.00 against a $43.25 price, so even the professionals disagree by 19% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Supernus Pharmaceuticals develops and sells prescription medicines for central nervous system conditions: ADHD, epilepsy, Parkinson's disease and, more recently, postpartum depression. The commercial model is straightforward specialty pharma. Supernus owns or licenses the products, runs its own US sales force calling on neurologists and psychiatrists, and books the revenue net of rebates and channel discounts. Its growth engine is Qelbree, a non-stimulant ADHD treatment that did ~$89 million in net sales in the second quarter of 2026 (up ~15%), alongside GOCOVRI for Parkinson's dyskinesia (~$38 million), ONAPGO, a continuous subcutaneous apomorphine infusion launched in 2025 (~$14 million), and collaboration revenue from ZURZUVAE for postpartum depression (~$35 million), which Supernus acquired when it bought Sage Therapeutics in mid-2025 and which it splits 50/50 with Biogen. Working against that are the legacy products: Trokendi XR and Oxtellar XR each fell ~25% year over year, APOKYN fell ~51%, and other older products fell ~71%. The financial picture as of August 2026 is a company whose reported numbers and adjusted numbers say different things. Second-quarter revenue was ~$219 million, up ~32%, and management raised full-year 2026 guidance to ~$860 million to ~$890 million in revenue and ~$150 million to ~$180 million in adjusted operating earnings. On a GAAP basis the same quarter produced a ~$58 million net loss, driven by a ~$55 million non-cash impairment of the APOKYN intangible plus ~$25 million of ongoing intangible amortization, and the full-year GAAP outlook was cut to an operating loss of ~$20 million to ~$50 million. The balance sheet holds ~$372 million in cash and marketable securities with no meaningful debt at the Supernus level. On top of that sits the August 2026 agreement to merge with Indivior, maker of the opioid-use-disorder treatment SUBLOCADE, in an all-stock deal targeting ~$2.2 billion of combined revenue, ~$888 million of EBITDA and ~$125 million of annual cost synergies, with closing targeted for the fourth quarter of 2026.
The bull case: what would have to be true for $67.00
The most optimistic published target on SUPN is $67.00, +54.9% from the $43.25 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Qelbree as the volume anchor in ADHD
Qelbree is the largest single product at ~$89 million in quarterly net sales and grew ~15% year over year. It is a non-stimulant, which gives it a distinct slot in a market still dominated by controlled-substance stimulants that face periodic supply and prescribing constraints. Growth has decelerated from the triple-digit rates of its launch years, so the question is whether it settles into steady mid-teens expansion or flattens as the addressable pool of stimulant-averse patients gets worked through.
2. ONAPGO and the device-delivered Parkinson's franchise
ONAPGO, approved in February 2025, is the first continuous subcutaneous apomorphine infusion cleared in the US for motor fluctuations in advancing Parkinson's. It reached ~$14 million in the quarter and guidance calls for ~$55 million to ~$70 million for the full year after supply constraints were resolved and new patient starts resumed. A regulatory submission for a second supplier was expected in the third quarter of 2026, with possible approval by mid-2027, which matters because single-source manufacturing is what interrupted the launch in the first place.
3. ZURZUVAE and the Sage acquisition
The July 2025 Sage acquisition brought ZURZUVAE, the only oral treatment approved for postpartum depression, into the portfolio. Supernus records 50% of Biogen's net revenue as collaboration revenue, which was ~$35 million in the quarter and carries no direct selling cost on the Supernus side. It is the highest-margin revenue line in the company and diversifies Supernus into neuropsychiatry, though it also means half the economics and none of the commercial control sit with a partner.
4. The Indivior merger of equals
The announced all-stock combination would exchange each Supernus share for 1.5401 Indivior shares, leaving Indivior holders with ~56.5% and Supernus holders with ~43.5% of a company targeting ~$2.2 billion in revenue and ~$125 million in annual cost synergies. Indivior brings SUBLOCADE and an opioid-use-disorder franchise, which is adjacent to but distinct from Supernus's neurology and psychiatry base. Indivior shareholders are also set to receive a ~$1 billion pre-closing special cash dividend funded in part by a ~$650 million term loan, so the combined entity would carry leverage that standalone Supernus does not.
The bear case: what would have to be true for $55.00
The most pessimistic published target is $55.00, +27.2% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Supernus Pharmaceuticals is worth if the risks below bite instead of the drivers above.
The legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue. Qelbree's US new-chemical-entity exclusivity ran out in April 2026 and Supernus received Paragraph IV notices from multiple generic filers in 2025, so the patents running from 2029 to 2035 now have to be defended in court rather than assumed. The merger itself carries real execution risk: it requires shareholder and regulatory approvals, adds leverage through the pre-closing special dividend, and hands Supernus holders a minority position in a business whose largest product serves opioid use disorder, a category with its own reimbursement and legal history. GAAP profitability is currently negative and management's own guidance sees a full-year operating loss, so the ~12x forward earnings multiple rests on adjusted figures that exclude impairments and amortization. Pipeline outcomes have disappointed before, including the SPN-820 miss in treatment-resistant depression in early 2025, and SPN-817 and SPN-820 remain in Phase 2b.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SUPN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on SUPN
4 analysts cover SUPN, with an average target of $62.50 (+44.5% against $43.25) and a split of 3 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SUPN forecast and price target page.
How is SUPN valued? (as of August 2026)
Snapshot for SUPN as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$830M
- Q2 2026 revenue: ~$219M, up ~32% year over year
- FY2026 revenue guidance: ~$860M to ~$890M
- FY2026 adjusted operating earnings guidance: ~$150M to ~$180M
- Net income (TTM): ~-$110M, or ~-$1.91 per share
- Market cap / cash: ~$2.5B market cap, ~$372M cash and marketable securities, no meaningful debt
At ~$43 per share the market values Supernus at roughly 2.4 times enterprise value to 2026 guided revenue and about 12 times forward earnings, which is a discount to profitable specialty pharma peers and reflects both the legacy-product decay and the pending merger. The GAAP loss is largely non-cash: a ~$55 million APOKYN impairment and ~$25 million per quarter of intangible amortization from prior acquisitions sit between adjusted operating earnings of ~$31 million in the quarter and the reported ~$58 million net loss. Because the Indivior exchange ratio is fixed at 1.5401 shares, the practical value of a Supernus share now moves with Indivior's price as much as with Supernus's own results.
How do you decide if SUPN is a buy?
Rather than asking whether SUPN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SUPN indirectly through an index or sector ETF before adding more.
What would change your mind on SUPN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Qelbree as the volume anchor in ADHD stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the SUPN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SUPN against your real portfolio and see your actual exposure before deciding.
Investing in Supernus Pharmaceuticals with AI
Connect the broker you already use and ask Walnut's AI how SUPN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is SUPN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Qelbree as the volume anchor in ADHD, with revenue (ttm) at ~$830M. The bear case rests on the legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue. Analysts covering it are spread from $55.00 to $67.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell SUPN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $55.00, +27.2% from the $43.25 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for SUPN?
+
Qelbree as the volume anchor in ADHD. Qelbree is the largest single product at ~$89 million in quarterly net sales and grew ~15% year over year. The most optimistic analyst target on SUPN is $67.00, +54.9% from the $43.25 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for SUPN?
+
The legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue. Qelbree's US new-chemical-entity exclusivity ran out in April 2026 and Supernus received Paragraph IV notices from multiple generic filers in 2025, so the patents running from 2029 to 2035 now have to be defended in court rather than assumed. The merger itself carries real execution risk: it requires shareholder and regulatory approvals, adds leverage through the pre-closing special dividend, and hands Supernus holders a minority position in a business whose largest product serves opioid use disorder, a category with its own reimbursement and legal history. GAAP profitability is currently negative and management's own guidance sees a full-year operating loss, so the ~12x forward earnings multiple rests on adjusted figures that exclude impairments and amortization. Pipeline outcomes have disappointed before, including the SPN-820 miss in treatment-resistant depression in early 2025, and SPN-817 and SPN-820 remain in Phase 2b. The most pessimistic published target is $55.00, +27.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Supernus Pharmaceuticals do?
+
Supernus Pharmaceuticals develops and sells prescription medicines for central nervous system conditions: ADHD, epilepsy, Parkinson's disease and, more recently, postpartum depression.
What would have to change for SUPN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Qelbree as the volume anchor in ADHD) stalling in the reported numbers rather than in the narrative, the risk above (the legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Supernus Pharmaceuticals actually sell?
+
Prescription central nervous system medicines. The four growth products are Qelbree (non-stimulant ADHD), GOCOVRI (Parkinson's dyskinesia), ONAPGO (continuous apomorphine infusion for advancing Parkinson's) and ZURZUVAE (oral postpartum depression treatment, revenue split with Biogen). Older products include Trokendi XR and Oxtellar XR for epilepsy, plus APOKYN, MYOBLOC and XADAGO.
Why did Supernus report a loss if revenue grew 32%?
+
The second-quarter 2026 net loss of ~$58 million was driven by a ~$55 million non-cash impairment of the APOKYN intangible asset, on top of ~$25 million of quarterly amortization from prior acquisitions. Adjusted operating earnings for the same quarter were ~$31 million. Management's full-year GAAP guidance still calls for an operating loss of ~$20 million to ~$50 million.
Walnut is informational, not investment advice, and gives no verdict on SUPN. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.